Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)

NCT00258570 | Recruiting DMC

• 1 other identifier: STUDY20030223
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The purposes of this study are:

• to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis;
• to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.

Conditions

Pulmonary Fibrosis

Keywords

"Lung[A04.400]"

Outcome Measures

Primary Outcomes (1)

• Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)

  Blood samples will be collected to validate in a large cohort the per- allele associations of prespecified SNPs with IPF case status adjusted for age , sex. smoking, and principal components of ancestry.

  Sample collection will occur up to 5 years based on the current rate of sample collection.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient population includes patients who have been diagnosed with a fibrotic interstitial lung disease who have been seen by a Simmons Center Physician.

You may qualify if:

• years of age or older
• Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest X-ray, and computed tomography (CT) scans.
• Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.

You may not qualify if:

• Under 18 years of age
• Non-fibrotic ILD

Sponsors & Collaborators

• University of Pittsburgh: lead

Study Sites (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

RECRUITING

Related Links

• The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease is designed to provide patient-friendly advice and support for people with idiopathic pulmonary fibrosis.

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples retained for multitude of testing. Consent allows for unrestricted use of samples.

MeSH Terms

Conditions

Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Kevin F Gibson, MD

  University of Pittsburgh, Simmons Center for ILD

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michelle F MacPherson, MAT

CONTACT

412-647-4537; macphersonmj@upmc.edu

Michelle Meyers, BSN

CONTACT

412-692-2149; meyersma@upmc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine

Study Record Dates

• First Submitted: November 23, 2005
• First Posted: November 24, 2005
• Study Start: January 1, 2003
• Primary Completion (Estimated): July 1, 2035
• Study Completion (Estimated): July 1, 2035
• Last Updated: November 12, 2025

Record last verified: 2025-09

Locations

US (1)